PPARA and metabolic dysfunction-associated steatohepatitis: When PPAR-α inhibitor was used, there was statistical significance of the differences between PIG and MG groups in most cases (p > 0.05) (Table 6 and Table 7), suggesting PPAR-α may play an important role in the progression of NASH.